secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001701541-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024
--------------------------------------------------------------------------------

- Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.
- Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.
- Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.
- ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.
- Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/0001701541-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000020/bdtx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001701541-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer